Shanghai’s Zai Lab (ZLAB) is adding a blood cancer drug to its pipeline through a licensing deal with the U.S. biotech giant Regeneron (REGN).
Zai Lab will help develop and commercialize the bispecific antibody REGN1979 for the China, Hong Kong, Taiwan, and Macau market. Under the terms of the deal, the Chinese biotech is paying $30 million up front and potentially as much as another $160 million if the therapy meets certain regulatory and commercial milestones.
